Scholarlink

<p><i>Limosilactobacillus reuteri</i> (<i>L. reuteri</i>) has probiotic advantages such as suppressing pathogenic bacteria, balancing the gut microbiota, regulating immunity, and having anti-inflammatory and antioxidant properties. This study explored its potential antibacterial and anti-inflammatory properties, isolating the bacterium from healthy pig feces. <i>L. reuteri</i> ZY18 was chosen due to its superior acid production, tolerance, and antibacterial characteristics. In vitro, the ZY18 strain had a survival rate of 46.00% in simulated gastric juice and efficiently inhibited enterotoxigenic Escherichia coli K88 (ETEC K88), with an inhibition zone measuring 1.90&#xa0;cm. In a mouse model challenged with ETEC K88, it demonstrated anti-inflammatory and antioxidant activities, as well as improved intestinal mechanical barrier integrity. Notably, the protective effects of ZY18 on the immune barrier were closely associated with the modulation of T helper 17 (Th17) cells and interleukin-17 (IL-17). These findings suggest that ZY18 has high antibacterial and anti-inflammatory capabilities, providing an associative basis that probiotic-based microbial products could be exploited as alternative therapeutic options for ETEC K88-related disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Functional Limosilactobacillus reuteri ZY18 Strain: Probiotic Properties and Associated Anti-inflammatory Responses Against ETEC K88 Infection

  • 期刊论文

  • 发表日期：

    2026年7月4日

查看全文
  • Xin Xu,
  • Jiahao Meng,
  • Hongwei Zhang,
  • Kun Meng,
  • Zihan Zhang,
  • Jiayi Sheng,
  • Hongying Cai,
  • Weiwei Liu,
  • Yunsheng Han,
  • Peilong Yang

摘要

Limosilactobacillus reuteri (L. reuteri) has probiotic advantages such as suppressing pathogenic bacteria, balancing the gut microbiota, regulating immunity, and having anti-inflammatory and antioxidant properties. This study explored its potential antibacterial and anti-inflammatory properties, isolating the bacterium from healthy pig feces. L. reuteri ZY18 was chosen due to its superior acid production, tolerance, and antibacterial characteristics. In vitro, the ZY18 strain had a survival rate of 46.00% in simulated gastric juice and efficiently inhibited enterotoxigenic Escherichia coli K88 (ETEC K88), with an inhibition zone measuring 1.90 cm. In a mouse model challenged with ETEC K88, it demonstrated anti-inflammatory and antioxidant activities, as well as improved intestinal mechanical barrier integrity. Notably, the protective effects of ZY18 on the immune barrier were closely associated with the modulation of T helper 17 (Th17) cells and interleukin-17 (IL-17). These findings suggest that ZY18 has high antibacterial and anti-inflammatory capabilities, providing an associative basis that probiotic-based microbial products could be exploited as alternative therapeutic options for ETEC K88-related disorders.